Ramos et al. in 2014, like others, have previously analysed SMARCA4 expression in a large series of 485 ovarian tumours including mainly serous high grade ovarian tumours,9,11,15 but only a few focused on other neoplasms that can mimic SCCOHT.13,14,16 It should be noticed that, in this large cohort, four percent (15/360) of clear cell ovarian cancers presented a loss of SMARCA4 protein, which could be expected as they present frequent SWI/SNF alterations (e.g. ARID1A mutations in 50–60%).21 This evidence concerns the gene ARID1A and ovarian neoplasm.